Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection.

Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection.

Detalhes bibliográficos
Principais autores:	Phillips, A, Walker, A
Formato:	Journal article
Idioma:	English
Publicado em:	2004

Registros relacionados

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
por: Nicola Gianotti, et al.
Publicado em: (2017-01-01)

Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients.
por: Mathieu Bastard, et al.
Publicado em: (2012-01-01)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
por: Fidler, S, et al.
Publicado em: (2002)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
por: Fidler, S, et al.
Publicado em: (2002)

HIV multi‐drug resistance at first‐line antiretroviral failure and subsequent virological response in Asia
por: Awachana Jiamsakul, et al.
Publicado em: (2014-01-01)

Drug monitoring of antiretroviral drugs in children with perinatal HIV infection
por: A. Yu. Sambyalova, et al.
Publicado em: (2024-07-01)

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
por: Ledergerber, B, et al.
Publicado em: (2004)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
por: Kekitiinwa, A, et al.
Publicado em: (2017)

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
por: Prendergast, A, et al.
Publicado em: (2008)

HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium
por: Georgette D. Kanmogne
Publicado em: (2024-04-01)

Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.
por: Pontiano Kaleebu, et al.
Publicado em: (2015-01-01)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
por: Annalisa Mondi, et al.
Publicado em: (2022-03-01)

Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia
por: Tee, K.K., et al.
Publicado em: (2006)

HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
por: Tsai HC, et al.
Publicado em: (2018-08-01)

Drug Resistance and Virological Failure among HIV-Infected Patients after a Decade of Antiretroviral Treatment Expansion in Eight Provinces of China.
por: Zhongbao Zuo, et al.
Publicado em: (2016-01-01)

Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania
por: Holberg-Petersen Mona, et al.
Publicado em: (2009-07-01)

Evaluating a minipool strategy to screen for virologic failure and antiretroviral drug resistance
por: H.M. Newman, et al.
Publicado em: (2014-04-01)

Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
por: Paris, D, et al.
Publicado em: (1999)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
por: Szubert, A, et al.
Publicado em: (2017)

Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda
por: Ahoua Laurence, et al.
Publicado em: (2009-06-01)

Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
por: Julie Kadima, et al.
Publicado em: (2018-01-01)

Food insecurity, drug resistance and non-disclosure are associated with virologic non-suppression among HIV pregnant women on antiretroviral treatment.
por: Bhavna H Chohan, et al.
Publicado em: (2021-01-01)

Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
por: Annelot F Schoffelen, et al.
Publicado em: (2013-01-01)

High rates of virological failure and drug resistance in perinatally HIV‐1‐infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo
por: Mounerou Salou, et al.
Publicado em: (2016-01-01)

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia
por: Olivier Segeral, et al.
Publicado em: (2010-01-01)

Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection
por: Kristen L. Bunnell PharmD, et al.
Publicado em: (2018-01-01)

Studying the Causes of Virologic Failure in the Early Stages of Antiretroviral Therapy in HIV-Infected Patients
por: M.H. Liulchuk
Publicado em: (2015-02-01)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
por: Alexander J Szubert, et al.
Publicado em: (2017-11-01)

Correction: Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
por: Julie Kadima, et al.
Publicado em: (2019-01-01)

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION
por: V. A. Chibilyaev, et al.
Publicado em: (2015-03-01)

Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations
por: Ziwei Chang, et al.
Publicado em: (2024-11-01)

HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial
por: Lisa Abuogi, et al.
Publicado em: (2023-10-01)

HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.
por: Francis Kiweewa, et al.
Publicado em: (2019-01-01)

Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.
por: Jallow, S, et al.
Publicado em: (2009)

Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya
por: Ingrid A. Beck, et al.
Publicado em: (2020-01-01)

Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action
por: Nicole A. Tillie, et al.
Publicado em: (2016-01-01)

Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study
por: Yiping Li, et al.
Publicado em: (2022-06-01)

Combination anti‐HIV antibodies to achieve antiretroviral therapy‐free virological suppression in infected individuals
por: M. Ali Rai, et al.
Publicado em: (2022-09-01)

Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy
por: Mulugeta Melku, et al.
Publicado em: (2020-08-01)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance
por: Charlotte Charpentier, et al.
Publicado em: (2023-02-01)